logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Exelixis and Aerie Have Good News

Exelixis & Aerie Have Good News Exelixis' Good News about Cabometyx Takeda Pharmaceuticals applied to the Japanese Ministry of Health, Labor and Welfare ( MHLW ) for approval to manufacture and to sell Exelixis’ ( EXEL ) product Cabometyx® (cabozantinib)...

Read More

April 25, 2019

0

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

A Great Day for B luebird bio and Celgene Read the Clinical Trial Results for Myeloma What a Great Day! Jobs reaching the moon. Inflation not yet showing any concerning signs. A fiercely rebounding stock market. Those who are still...

Read More

May 3, 2019

0

Will the Bear Escape Tonight from the Market? Regeneron and Severe Asthma Patients Good News

The Stock Market The Confused and Confusing Stock Market The stock market is confused and confusing. No analysts’ speculations are materializing and no satisfactory explanations for the market’s agitation and selloff. Although not an unprecedented situation, what makes it strange...

Read More

May 9, 2019

0

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and Vemlidy from Gilead Sciences Succeed in Treating Chronic Hepatitis B Viral Infection

Spring Bank Pharmaceuticals, Gilead Sciences and HBV If Spring Bank Pharmaceuticals' ( SBPH ) product inarigivir in combination with Gilead Sciences' ( GILD ) Vemlidy® could validate the current encouraging results of the ongoing trials on chronic hepatitis B virus...

Read More

October 24, 2019

0

Advaxis: Why This Small Firm's Stock Outperformed on a Negative Market Day

Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ ( ADXS ) stock rallied today as the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its product  AIM2CERV ( axalimogene filolisbac ). The product is in...

Read More

May 15, 2019

0

Vertex: Good News and Good Decisions

Vertex's Good News Vertex and Kymera Therapeutics Collaboration Last week   Vertex Pharmaceuticals ( VRTX ) and Kymera Therapeutics entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets . Kymera  is...

Read More

May 23, 2019

0

When Negative Reactions to Biotechnology News Mislead. The Case of Regenxbio.

Regenxbio Misleading Selloff A selloff of Regenxbio ( RGNX ) stock, following the FDA’s partial hold on the intrathecal administration of AVXS-101, is unwarranted and totally misleading.   Why? Because the selloff of RGNX gave the impression that the gene...

Read More

October 31, 2019

0

Exelixis: The European Commission approves Cabometix for first line treatment of poor-risk advanced renal cell carcinoma

Exelixis (EXEL)  announced that its partner Ipsen received approval from the European Commission (EC) for  CABOMETYX ® (cabozantinib) 20 mg, 40 mg and 60 mg   for the first-line treatment of adults with intermediate or poor-risk advanced renal cell carcinoma (RCC) in the European Union....

Read More

May 17, 2018

0

An FDA Advisory Committee Voted in Favor of Approving Akcea Therapeutics’ Product, WAYLIVRA, for FCS Syndrome.

Ionis Pharmaceuticals (IONS)  and   Akcea Therapeutics (AKCA) ,  an affiliate of Ionis Pharmaceuticals, announced that the Advisory Committee of the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products voted 12-8 in support of approving the firms’ product ...

Read More

May 14, 2018

0

CARA Therapeutics has good news

Cara Therapeutics (CARA)  develops novel and proprietary class of product candidates, led by  Korsuva  (CR845/difelikefalin) injection. This product is a first-in-class peripheral kappa opioid receptor (KOR) agonist designed to alleviate pruritus (itching) and pain.   In Phase 2 trials,  Korsuva injection...

Read More

May 23, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 67
  • 68
  • 69
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy